+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID06371274

Study of Oral All-trans Retinoic Acid and Toripalimab for Women with Advanced or Metastatic Triple-negative Breast Cancer After Prior Treatments

Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-12

29

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical effects and safety of combining oral all-trans retinoic acid with toripalimab in women with advanced triple-negative breast cancer that cannot be removed by surgery, has returned, or spread to other parts of the body after failing standard second-line or later treatments. This study is a single-arm, open-label trial conducted at one center, aiming to enroll 32 participants to better understand this combination therapy in this patient group. Participants will take all-trans retinoic acid orally at a dose of 150 mgm2 twice daily for three consecutive days in each 3-week cycle. On day 1 of each cycle, they will also receive an intravenous infusion of toripalimab at 240 mg. Treatment cycles continue every three weeks until the disease worsens, unacceptable side effects occur, loss to follow-up, death, or other withdrawal reasons, for up to two years. The study includes a screening period up to 28 days to confirm eligibility and baseline assessments. During treatment, tumor scans using contrast-enhanced CT will be done every 6 weeks to evaluate response using RECIST 1.1 and iRECIST criteria. Safety will be monitored by observing side effects according to standard criteria up to 30 days after the last treatment. After treatment ends, participants will be followed for survival every three months to measure outcomes including response rate, progression-free survival, duration of response, and overall survival, with total follow-up up to two years.

CONDITIONS

Brief Title

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Research Team

J

Jian Liu, MS

M

Meihua Lin, MS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here